Benzamide,4-[(6-nitro-4-quinolinyl)amino]-N-[4-(4-pyridinylamino)phenyl]- manufacturers
- T3Inh-1
-
- $115.00 / 1mg
-
2024-11-15
- CAS:50440-30-7
- Min. Order:
- Purity: 97%
- Supply Ability: 10g
|
| | Benzamide,4-[(6-nitro-4-quinolinyl)amino]-N-[4-(4-pyridinylamino)phenyl]- Basic information |
| Product Name: | Benzamide,4-[(6-nitro-4-quinolinyl)amino]-N-[4-(4-pyridinylamino)phenyl]- | | Synonyms: | Benzamide,4-[(6-nitro-4-quinolinyl)amino]-N-[4-(4-pyridinylamino)phenyl]-;T3Inh-1;50440-30-7 Benzamide,4-[(6-nitro-4-quinolinyl)amino]-N-[4-(4-pyridinylamino)phenyl]-;T3Inh1,T3Inh 1,inhibit,O-glycosylation,Inhibitor,T-3Inh-1,ppGalNAc-T3,breast cancer cells,FGF23,T3Inh-1,invasion;4-(6-Nitro-quinolin-4-ylamino)-N-[4-(pyridin-4-ylamino)-phenyl]-benzamide;T3Inh-1, 10 mM in DMSO | | CAS: | 50440-30-7 | | MF: | C27H20N6O3 | | MW: | 476.49 | | EINECS: | | | Product Categories: | | | Mol File: | 50440-30-7.mol | ![Benzamide,4-[(6-nitro-4-quinolinyl)amino]-N-[4-(4-pyridinylamino)phenyl]- Structure](CAS/20180601/GIF/50440-30-7.gif) |
| | Benzamide,4-[(6-nitro-4-quinolinyl)amino]-N-[4-(4-pyridinylamino)phenyl]- Chemical Properties |
| Boiling point | 662.7±55.0 °C(Predicted) | | density | 1.431±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO : 31.25 mg/mL (65.58 mM; ultrasonic and warming and heat to 60°C) | | pka | 13.21±0.70(Predicted) | | form | Solid | | color | Yellow to brown |
| | Benzamide,4-[(6-nitro-4-quinolinyl)amino]-N-[4-(4-pyridinylamino)phenyl]- Usage And Synthesis |
| Uses | T3Inh-1 is a potent and selective inhibitor of ppGalNAc-T3 (IC50=7 μM). T3Inh-1 reduces FGF23 hormone levels in both tissue cells and mice, without causing any toxic side effects. T3Inh-1 also prevents breast cancer cells. The enzyme ppGalNAc-T3 is implicated in at least two medically important pathways: cancer metastasis and stabilization of FGF23 (regulates phosphate levels in the bloodstream)[1]. | | in vivo | T3Inh-1 (25 or 50 mg/kg; i.p.) blocks ppGalNAc-T3-mediated glycan-masking of FGF23 thereby increasing its cleavage[1]. | Animal Model: | Wild-type C57BL/6 six to eight week old mice[1] | | Dosage: | 25 or 50 mg/kg | | Administration: | Intraperitoneal injection (Dissolved in DMSO at 25 and 50 mg/ml then further diluted with PEG400 to create 5 and 10 mg/ml stocks for injection) | | Result: | Caused a robust and statistically significant increase the ratio of cleaved/intact FGF23 at the tested 25 and 50 mg/kg concentrations.
|
| | References | [1] Song L, et al. Inhibitor of ppGalNAc-T3-mediated O-glycosylation blocks cancer cell invasiveness and lowers FGF23 levels. Elife. 2017;6:e24051. Published 2017 Mar 31. DOI:10.7554/eLife.24051 |
| | Benzamide,4-[(6-nitro-4-quinolinyl)amino]-N-[4-(4-pyridinylamino)phenyl]- Preparation Products And Raw materials |
|